

Substitute for form 1449/PTO		<b>Complete If Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/667,096-Conf. #1638
		<b>Filing Date</b>	September 18, 2003
		<b>First Named Inventor</b>	Brian R. MacDonald
		<b>Art Unit</b>	1647
		<b>Examiner Name</b>	B. E. Bunner
		<b>Attorney Docket Number</b>	026038.0376PTUS
Sheet	1	of	4

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number/Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1*	US-2002/0187124-A1	12-12-2002	Takahashi	
	2*	US-2003/0158116-A1	08-21-2003	Dower et al.	
	3*	US-2004/0028649-A1	02-12-2004	Gianni	
	4*	US-2005/0137133-A1	06-23-2005	MacDonald et al.	
	5*	US-2006/0040866-A1	02-23-2006	MacDonald et al.	
	6*	US-2008/0119384-A1	05-22-2008	Yurkow et al.	
	7*	US-3,654,090	04-04-1972	Wilhelmus et al.	
	8*	US-3,940,475	02-24-1976	Gross	
	9*	US-4,179,337	12-18-1979	Davis et al.	
	10*	US-4,301,144	11-17-1981	Iwashita et al.	
	11*	US-4,496,689	01-29-1985	Mitra	
	12*	US-4,612,132	09-16-1986	Wollenberg et al.	
	13*	US-4,640,835	02-03-1987	Shimizu et al.	
	14*	US-4,668,619	05-26-1987	Greenquist et al.	
	15*	US-4,670,417	06-02-1987	Iwasaki et al.	
	16*	US-4,791,192	12-13-1988	Nakagawa et al.	
	17*	US-5,198,424	03-30-1993	McEver	
	18*	US-5,359,115	10-25-1994	Campbell et al.	
	19*	US-5,420,328	05-30-1995	Campbell	
	20*	US-5,424,186	06-13-1995	Fodor et al.	
	21*	US-5,432,018	07-11-1995	Dower et al.	
	22*	US-5,639,603	06-17-1997	Dower et al.	
	23*	US-5,723,286	03-03-1998	Dower et al.	
	24*	US-5,770,358	06-23-1998	Dower et al.	
	25*	US-5,989,833	11-23-1999	Charon et al.	
	26*	US-7,189,827	03-13-2007	Feige	
	27*	In the U. S. Patent and Trademark Office Application No. 10/083,768 Non-Final Office Action dated February 25, 2005, 8 pages.			
	28*	In the U. S. Patent and Trademark Office Application No. 10/918,561 Non-Final Office Action dated March 30, 2007, 11 pages.			
	29*	In the U. S. Patent and Trademark Office Application No. 10/918,561 Non-Final Office Action dated November 27, 2007, 21 pages.			
	30*	In the U. S. Patent and Trademark Office Application No. 10/918,561 <i>Ex parte Quayle</i> Action dated September 4, 2008, 7 pages.			
	31*	In the U. S. Patent and Trademark Office Application No. 11/200,416 Non-Final Office Action dated January 7, 2009, 27 pages.			
	32*	In the U. S. Patent and Trademark Office Application No. 11/254,419 Non-Final Office Action dated June 27, 2006, 6 pages.			
	33*	In the U. S. Patent and Trademark Office Application No. 11/354,065 Non-Final Office Action dated July 22, 2008, 28 pages.			
	34*	In the U. S. Patent and Trademark Office Application No. 11/610,226 Non-Final Office Action dated April 29, 2010, 22 pages.			
	35*	In the U. S. Patent and Trademark Office Application No. 11/818,049 Non-Final Office Action dated February 18, 2009, 11 pages.			
	36*	In the U. S. Patent and Trademark Office Application No. 12/103,377 Non-Final Office Action dated June 7, 2010, 11 pages.			
	37*	In the U. S. Patent and Trademark Office Application No. 12/103,377 Final Office Action dated December 13, 2010, 15 pages.			

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/667,096-Conf. #1638
		<b>Filing Date</b>	September 18, 2003
		<b>First Named Inventor</b>	Brian R. MacDonald
		<b>Art Unit</b>	1647
		<b>Examiner Name</b>	B. E. Bunner
		<b>Attorney Docket Number</b>	026038.0376PTUS
Sheet	2	of	4

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)					
	38	EP-0	450 715-A1	10-09-1991	Eniricerche Spa		
	39	EP-0	783 003-A1	07-09-1997	Kyowa Hakko Kogyo Kk		
	40	GB-2	186 579-A	08-19-1987	Foxwell Brian Maurice John et al.		
	41	WO-02/05	1861-A2	07-04-2002	Kinerton Ltd et al.		
	42	WO-04/026332	A1	04-01-2004	3-Dimensional Pharm Inc		
	43	WO-05/023834	A2	03-17-2005	3-Dimensional Pharm Inc et al.		
	44	WO-95/05843	A1	03-02-1995	Systemix Inc et al.		
	45	WO-95/34326	A1	12-21-1995	Kohno Tadahiko et al.		
	46	WO-96/14293	A1	05-17-1996	Santen Pharma Co Ltd et al.		
	47	WO-96/34016	A1	10-31-1996	Kyowa Hakko Kogyo Kk et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.58(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IPW. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/667,096-Conf. #1638
		<b>Filing Date</b>	September 18, 2003
		<b>First Named Inventor</b>	Brian R. MacDonald
		<b>Art Unit</b>	1647
		<b>Examiner Name</b>	B. E. Bunner
		<b>Attorney Docket Number</b>	026038.0376PTUS
<b>Sheet</b>	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	48	CASE et al., "The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large-Animal Model of Chemotherapy-Induced Thrombocytopenia," <i>Stem Cells</i> , 2000; 18:360-365.	
	49	DE SERRES et al., "Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Thrombopoietin Neutralizing Antibody Production in Man," <i>Stem Cells</i> , 1999; 17:203-209	
	50	DE SERRES et al., "Pharmacokinetics and Hematological Effects of the PEGylated Thrombopoietin Peptide Mimetic GW395058 in Rats and Monkeys after Intravenous or Subcutaneous Administration," <i>Stem Cells</i> , 1999; 17:316-326.	
	51	HORVATH et al., "Synthesis and Biological Activity of LH-RH Antagonists Modified in Position 1," <i>Peptides</i> , 1982; 3:969-971.	
	52	HRUBY et al., "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations," <i>Biochem J.</i> , 1990; 268:249-262.	
	53	HRUBY, Victor J., "Conformational Restrictions of Biologically Active Peptides Via Amino Acid Side Chain Groups," <i>Life Sci.</i> , Pergamon Press, 1982; 31:189-199.	
	54	HUDSON et al., "Methionine Enkephalin and Isosteric Analogues," <i>Int. J. Pept. Prot. Res.</i> , 1979; 14:177-185.	
	55	KAUSHANSKY, Kenneth, "Hematopoietic Growth Factor Mimetics," <i>Annals of the New York Academy of Sciences</i> , 2001; 938:131-138.	
	56	KAUSHANSKY, Kenneth, "Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic Stem Cell," <i>Annals of the New York Academy of Sciences</i> , 2003; 996:39-43 (Abstract)	
	57	KORBLING et al., "Autologous Transplantation of Blood-Derived Hemopoietic Stem Cells After Myeloablative Therapy in A Patient with Burkitt's Lymphoma," <i>Blood</i> , 1986; 67:529-532.	
	58	LAJTHA, L. G., "Haemopoietic Stem Cells: Concepts and Definitions," <i>Blood Cells</i> , 1979; 5:447-455.	
	59	LAJTHA, L. G., "Stem Cell Concepts," <i>Differentiation</i> , 1979; 14:23-34.	
	60	LIN et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <i>Science Reports</i> , 1990; 249:677-679.	
	61	LUTHMAN et al., "Peptides and Peptidomimetics," <i>A Textbook of Drug Design and Development</i> , 2nd Edition, Harwood Academic Publishers GmbH, 1996; 14:386-406.	
	62	MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> , 1963; 85:2149.	
	63	MONFARDINI et al., "A Branched Monomethoxypoly(ethylene glycol) for Protein Modification," <i>Bioconjugate Chem.</i> , 1995; 6:62-69.	
	64	MORGAN et al., "Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases," <i>Ann. Rep. Med. Chem.</i> , 1989; 24:243-252.	
	65	MORLEY, "Modulation of the Action of Regulatory Peptides by Structural Modification," <i>Trends in Pharm Sci.</i> , 1980; 463-468.	
	66	NOTHDURFT et al., "Studies on the Regeneration of the CFU-C Population in Blood and Bone Marrow of Lethally Irradiated Dogs After Autologous Transfusion of Cryopreserved Mononuclear Blood Cells," <i>Scand. J. Haematol.</i> , 1977; 19:470-481.	
	67	OCHS et al., "952 Immune Reconstitution in Adenosine Deaminase Deficient Severe Combined Immune Deficiency," <i>Pediatr. Res.</i> , 1981; 15(4):601.	
	68	PAIGE et al., "Precursors of Murine B Lymphocytes," <i>J. Exp. Med.</i> , 1981; 153:154-165.	
	69	PIETTA et al., "Amide Protection and Amide Supports in Solid-Phase Peptide Synthesis," <i>Chem. Comm.</i> , 1970; 650-651.	

Substitute for form 1449/PTO		<b>Complete If Known</b>			
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/667,096-Conf. #1638		
		<b>Filing Date</b>	September 18, 2003		
		<b>First Named Inventor</b>	Brian R. MacDonald		
		<b>Art Unit</b>	1647		
		<b>Examiner Name</b>	B. E. Bunner		
<b>Sheet</b>	4	<b>of</b>	4	<b>Attorney Docket Number</b>	026038.0376PTUS

70	PROCHAZKA et al., "The 1- and 2-Naphthylalanine Analogs of Oxytocin and Vasopressin," <i>Collect. Czech. Chem. Commun.</i> , 1995; 60:2170-2177.
71	PRUMMER et al., "Recovery of Immune Functions in Dogs After Total Body Irradiation and Transplantation of Autologous Blood or Bone Marrow Cells," <i>Exp. Hematol.</i> , 1985; 13:891-898.
72	RAGHARACHAR et al., "Comparison of the Repopulating Potential of Stem Cells Derived from Blood and Bone Marrow: Autotransplants in Dogs," <i>J. Cell. Biochem. Suppl.</i> , 1983; Poster Session 0198:78.
73	REIFFERS et al., "Successful Autologous Transplantation With Peripheral Blood Hemopoietic Cells In A Patient With Acute Leukemia," <i>Exp. Hematol.</i> , 1986; 14:312-315.
74	RENSCHLER et al., "Synthetic Peptide Ligands of the Antigen Binding Receptor Induce Programmed Cell Death in a Human B-Cell Lymphoma," <i>Immunology</i> , 1994; 91:3623-3627.
75	ROBERTS et al., "Unusual Amino/Acids in Peptide Synthesis," <i>The Peptides</i> , Academic Press, 1983; 5(Chapter 6):341-449.
76	SARPEL et al., "The Collection, Preservation and Function of Peripheral Blood Hematopoietic Cells in Dogs," <i>Exp. Hematol.</i> , 1979; 7(2):113-120.
77	SINGER et al., "Pegylated Thrombopoietin (TPO)-Mimetic Peptides Bind Human to TPO Receptor Causing Proliferation and Maturation of Megakaryocytes <i>In Vitro</i> ," 1998; Abstract #2336(Poster Board Session # 193-IV):568A.
78	SPATOLA et al., "Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates," <i>Life Sci.</i> , 1986; 38:1243-1249.
79	SPATOLA et al., <i>Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins</i> , B Weinstein, eds., Marcel Dekker, New York, 1983; 267-356.
80	TILLY et al., "Haemopoietic Reconstitution After Autologous Peripheral Blood Stem Cell Transplantation In Acute Leukaemia," <i>The Lancet</i> , 1986; 328(8499):154-155.
81	TO et al., "Peripheral Blood Stem Cell Autografting: A New Therapeutic Option for AML?" <i>Brit. J. Haematol.</i> , 1987; 66:285-288.
82	TULUNAY et al., "Protection of Lethally Irradiated Mice with Allogeneic Fetal Liver Cells: Influence of Irradiation Dose on Immunologic Reconstitution," <i>Proc. Nat. Acad. Sci.</i> , 1975; 72(10):4100-4104.
83	VICKERY et al., "Effect Of Immune Reconstitution On Resistance To <i>Brugia Pahangi</i> In Congenitally Athymeric Nude Mice," <i>J. Parasitol.</i> , 1983; 69(3):478-485.
84	WEANER et al., "Tritium Labeling of N-Protected Amino Acids And Peptides Containing O-Alkyl-Tyrosyl Residues," <i>Synthesis and Applications of Isotopically Labelled Compounds</i> , 1994; 137-140.
85	WRIGHTON et al., "Small Peptide Mimetics of Erythropoietin," <i>Blood, Suppl 1</i> , 1996; 88(10):543a, Abstract 2160.
86	WRIGHTON et al., "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin," <i>Science</i> , 1996; 273:458-463.
87	ZALUPSKY et al., "Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates," <i>Bioconjugate Chem.</i> , 1995; 6:150-165.

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.